
Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.

Himisha Beltran, MD, discusses the limitations of tissue biopsies versus liquid biopsies in castration-resistant neuroendocrine prostate cancer.

Himisha Beltran, MD, discusses profiling of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Published: November 9th 2020 | Updated:

Published: November 3rd 2020 | Updated:

Published: February 25th 2020 | Updated:

Published: April 8th 2020 | Updated:

Published: April 25th 2020 | Updated:

Published: April 29th 2020 | Updated: